Compounded vs Brand-Name GLP-1: Why Medicare Only Covers One

If you have been researching GLP-1 medications online, you have almost certainly come across advertisements for compounded semaglutide or compounded tirzepatide at prices far below the brand-name retail cost. Compounded versions can cost $200 to $400 per month compared to $1,000 or more for Wegovy or Zepbound. The price difference is striking — and it raises an obvious question: why not just use the cheaper compounded version? The answer matters, especially for Medicare seniors, because the Bridge program will not cover compounded GLP-1 medications. Here is why.

What is compounded semaglutide?

Compounding is the process of creating a custom medication by combining, mixing, or altering ingredients in a specialized pharmacy. Compounded semaglutide is made by compounding pharmacies that purchase the raw semaglutide base ingredient and formulate it into injectable or oral forms — essentially creating their own version of the medication outside of the normal FDA-approved manufacturing process.

Compounding has a legitimate and important role in medicine — it allows pharmacists to create customized medications for patients with specific needs, such as allergen-free formulations, liquid versions of medications that only come in pills, or pediatric dosing. However, compounding a medication that is readily available from the original manufacturer in its FDA-approved form raises different questions.

Why are compounded versions cheaper?

The cost difference exists because compounding pharmacies do not bear the costs that FDA-approved manufacturers do:

• No clinical trials — Novo Nordisk spent billions on the STEP trials to prove semaglutide is safe and effective. Compounding pharmacies use that data without conducting their own trials.
• No FDA approval process — the multi-year, multi-billion-dollar FDA approval process is bypassed entirely.
• No patent licensing fees — compounding pharmacies create their own formulations using bulk ingredients.
• No post-market surveillance requirements — FDA-approved manufacturers must track and report adverse events. Compounders have much lighter reporting obligations.
• Simpler manufacturing — compounding pharmacies operate under different regulations than large-scale pharmaceutical manufacturers.

The safety concerns with compounded GLP-1 medications

The FDA has issued multiple warnings about compounded semaglutide and tirzepatide products. The key safety concerns include:

No FDA review of the specific product

When you receive FDA-approved Wegovy, every batch has been manufactured under FDA-inspected conditions with verified potency, purity, and sterility. Compounded versions have not undergone this level of scrutiny. The active ingredient may be the same molecule, but the final product — including its formulation, concentration, sterility, and stability — has not been reviewed or approved by the FDA.

Dosing inconsistency

Compounded medications may not contain the exact concentration labeled. If the compounding process is imprecise, you could receive too much or too little medication in each injection. With GLP-1 medications, where precise dosing and gradual titration are critical for managing side effects, inconsistent dosing is a meaningful safety risk.

Sterility and contamination

Injectable medications must be sterile. FDA-approved manufacturing facilities operate under strict sterile conditions (Current Good Manufacturing Practices). Compounding pharmacies operate under different standards that vary by state. The FDA has documented cases of contaminated compounded injectable medications causing serious infections, hospitalizations, and deaths — most notably the 2012 fungal meningitis outbreak from a compounding pharmacy in Massachusetts that killed 76 people.

Salt form differences

Some compounded products use semaglutide sodium (a salt form) rather than the semaglutide base used in FDA-approved Wegovy. The FDA has stated that semaglutide sodium is a different substance from the FDA-approved ingredient and that compounded products using this salt form are not equivalent to the approved medication. The clinical implications of this difference are not fully understood.

Why Medicare will not cover compounded GLP-1 medications

The Medicare Bridge program specifically covers FDA-approved brand-name GLP-1 medications — Wegovy, Zepbound, and Foundayo. Compounded versions are excluded for several reasons:

• Medicare Part D only covers FDA-approved prescription drugs — this is a fundamental rule of the program, not specific to GLP-1 medications.
• The Bridge program requires prior authorization through a central processor — the system is designed to work with standardized FDA-approved products, not custom-compounded formulations.
• Safety and liability — Medicare cannot verify the safety, potency, or consistency of compounded products in the way it can for FDA-approved medications.
• The FDA-approved products have clinical trial data proving efficacy and safety — compounded versions do not have independent proof of equivalent outcomes.

Does the Bridge program make compounded versions unnecessary?

For Medicare beneficiaries who qualify for the Bridge program, the answer is largely yes. The $50 monthly copay for FDA-approved Wegovy or Zepbound eliminates the primary reason people seek compounded alternatives — cost. At $50 per month for a medication that has been rigorously tested in clinical trials involving tens of thousands of patients, the value proposition is clear.

If you are currently using a compounded GLP-1 and want to switch to an FDA-approved version through the Bridge program, discuss the transition with your doctor. They will need to evaluate your current dose, submit a prior authorization, and may adjust your treatment plan during the switch.

What about people who do not qualify for the Bridge program?

For people who do not have Medicare or do not meet Bridge program eligibility criteria, the cost of brand-name GLP-1 medications remains a significant barrier. In those situations, compounded versions may be the only affordable option — and many patients and physicians choose them knowingly after weighing the risks and benefits. That is a decision between you and your doctor.

However, if you do use a compounded product, verify that the compounding pharmacy is licensed in your state, preferably accredited by the Pharmacy Compounding Accreditation Board (PCAB), and compliant with USP 797 and 800 standards for sterile compounding. These certifications do not guarantee FDA-level quality, but they indicate a higher standard of practice.

Whether you are on a compounded or brand-name GLP-1 medication, tracking your daily health data on CairnSpace — weight, meals, symptoms, and side effects — provides a consistent record that helps your doctor monitor your response to treatment regardless of the source of your medication.

Related Articles

• Does Medicare Cover GLP-1 Weight Loss Medications in 2026?
• What Does a GLP-1 Medication Actually Cost on Medicare After July 2026?
• The Medicare GLP-1 Bridge Program: What It Is, Who Qualifies, and How to Enroll
• Wegovy vs Zepbound: Which GLP-1 Is Right for Seniors on Medicare?

Sources

• FDA — warnings about compounded semaglutide and tirzepatide products (2023-2024)
• FDA — statement on semaglutide sodium salt form vs. semaglutide base
• Centers for Medicare and Medicaid Services — Medicare Part D covered drug requirements
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation standards
• Centers for Disease Control and Prevention — 2012 multistate fungal meningitis outbreak from compounded medications